The rare aggressive pituitary adenoma presents a special challenge, due to the heterogenous presentation of the disease. The prognosis of aggressive pituitary adenomas has been improved due to recent studies demonstrating clinically-relevant efficacy of temozolomide, which is now considered first-line chemotherapy. However, there is limited data on second-line therapies in patients with treatment failure. This review presents a summary on the potential of medical therapies in aggressive pituitary tumors.

中文翻译：

---

侵袭性垂体瘤的药物治疗

由于疾病的异质性表现，罕见的侵袭性垂体腺瘤提出了特殊的挑战。由于最近的研究证明了替莫唑胺的临床相关疗效，侵袭性垂体腺瘤的预后得到了改善，替莫唑胺现在被认为是一线化疗。然而，关于治疗失败患者二线治疗的数据有限。本综述总结了药物治疗侵袭性垂体瘤的潜力。